TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36247059
Drug: PBM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM therapy (Dose A: 3.75 J/cm²)
Study: 36247059
Drug: PBM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM therapy (Dose B: not specified)
Study: 36247452
Drug: Daily steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily steps ≥7,500
Study: 36247452
Drug: Daily steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily steps ≥10,000
Study: 36247744
Drug: FDC formulation
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC formulation containing raloxifene 60 mg and cholecalciferol 800 IU
Study: 36247744
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of raloxifene and cholecalciferol
Study: 36247822
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin
Study: 36247923
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg intravenously Q2W
Study: 36248617
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine (two doses)
Study: 36248865
Drug: Neoantigen vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoantigen vaccination after local RFA treatment
Study: 36248865
Drug: Neoantigen vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoantigen vaccination without prior RFA treatment
Study: 36249526
Drug: Citalopram (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (single dose)
Study: 36249705
Drug: GEM103 (Recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM103 (Recombinant Human Complement Factor H) at doses of 50 μg/eye, 100 μg/eye, 250 μg/eye, or 500 μg/eye
Study: 36250418
Drug: Adjunctive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapies plus land-based exercise therapy
Study: 36250418
Drug: Adjunctive electrophysical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive electrophysical agents plus exercise
Study: 36250418
Drug: Adjunctive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapies plus exercise
Study: 36251220
Drug: Cemiplimab monotherapy
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab monotherapy (350 mg every 3 weeks intravenously)
Study: 36251376
Drug: No nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nutritional supplement (Control)
Study: 36251401
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy-General (FACT-G), SF-36, EQ-5D
Study: 36251766
Drug: ORADUR-Methylphenidate, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORADUR-Methylphenidate, dosage and duration not available
Study: 36252789
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of mRNA COVID-19 vaccine
Study: 36252789
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of mRNA COVID-19 vaccine
Study: 36252870
Drug: ML EGD
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML EGD (machine learning-based model)
Study: 36252998
Drug: T-DM1 plus
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 plus pembrolizumab (3.6 mg/kg T-DM1 every 21 days plus 200 mg pembrolizumab every 21 days)
Study: 36253834
Drug: Tobacco dependence
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco dependence treatment (TDT) intervention counseling
Study: 36253875
Drug: Multidisciplinary assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary assessment and standardized treatment
Study: 36253875
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of embolization and SRS
Study: 36255372
Drug: Eltrombopag (ELT)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (ELT) monotherapy
Study: 36255372
Drug: Lenalidomide (LEN)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide (LEN) monotherapy
Study: 36256599
Drug: Venglustat 15
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat 15 mg once-daily in combination with imiglucerase enzyme replacement therapy
Study: 36256671
Drug: Colchicine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.05 mg/kg orally once daily before or after collagenase-induced ICH
Study: 36256988
Drug: Family Constellation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family Constellation Therapy
Study: 36259253
Drug: Lazertinib as
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib as consolidation therapy
Study: 36259527
Drug: Protease Inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease Inhibitors (Control)
Study: 36259971
Drug: B7-H3 CAR
Normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B7-H3 CAR T cells, administered as 40 infusions, repeated locoregional dosing.
Study: 36261215
Drug: Amplivant-conjugated HPV16-SLP
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amplivant-conjugated HPV16-SLP vaccine (1, 5, 20 or 50 µg per conjugated peptide)
Study: 36261215
Drug: Amplivant-conjugated HPV16-SLP
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amplivant-conjugated HPV16-SLP vaccine (highest dose group)
Study: 36261215
Drug: Amplivant-conjugated HPV16-SLP
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amplivant-conjugated HPV16-SLP vaccine (various doses)
Study: 36261583
Drug: Serplulimab 3
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab 3 mg/kg every 2 weeks for up to 52 cycles
Study: 36261602
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (revascularization and/or intestinal resection)
Study: 36261752
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for high-risk stage II and stage III patients
Study: 36261752
Drug: Curative-intent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative-intent treatment
Study: 36263685
Drug: Serum cortisol1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum cortisol1 mg DST
Study: 36263839
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without PET/CT
Study: 36263840
Drug: KTE-X19 (1×10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTE-X19 (1×10^6 CAR T cells/kg in 68 mL formulation)
Study: 36263840
Drug: KTE-X19 (1×10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTE-X19 (1×10^6 CAR T cells/kg in 40 mL formulation)
Study: 36264123
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg/300 mg once daily + osimertinib 80 mg once daily
Study: 36264123
Drug: Savolitinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib + osimertinib combination
Study: 36264125
Drug: Vonoprazan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (10 mg once daily)
Study: 36264382
Drug: Sapanisertib (TAK-228)
Normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib (TAK-228) 3 mg by mouth once daily on a continuous dosing schedule in 28-day cycle
Study: 36264536
Drug: Moderate CYP3A4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate CYP3A4 inhibitor (fluconazole)
Study: 36264905
Drug: Pfizer-BioNTech BNT162b2
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech BNT162b2 vaccine
Study: 36264995
Drug: Involvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement of pharmacists in the care trajectory of older adults with MNCDs in family medicine groups (FMGs)
Study: 36265087
Drug: Venetoclax 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 600 mg + Idasanutlin 150 mg
Study: 36265087
Drug: Venetoclax 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 600 mg + Idasanutlin 200 mg
Study: 36265087
Drug: Venetoclax (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (various doses) + Idasanutlin (days 1-5 in 28-day cycles)
Study: 36265128
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment for CLL in the last 12 months
Study: 36265185
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of changes in WHO class, BNP, and RV global AS.
Study: 36265962
Drug: Subcutaneous Implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Implantable Cardioverter-Defibrillator Therapy
Study: 36265962
Drug: Transvenous Implantable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvenous Implantable Cardioverter-Defibrillator Therapy
Study: 36266001
Drug: ICD-detected sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD-detected sleep apnea (measured by weekly mean RDI)
Study: 36266001
Drug: Weekly mean
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly mean RDI of ≥45 episodes/h
Study: 36267207
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Vitamin D3
Study: 36267741
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg per day
Study: 36269382
Drug: Isoproterenol (ISO)
Normalized name: isoproterenol sulfate Metered Dose Inhaler [Medihaler-Iso]
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol (ISO) injections
Study: 36269530
Drug: Pre-chemotherapy IL-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy IL-8
Study: 36269530
Drug: Pre-chemotherapy TNF-α
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-chemotherapy TNF-α
Study: 36269530
Drug: Chemotherapy duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy duration above 20 weeks
Study: 36269530
Drug: Chemotherapy dose
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy dose
Study: 36269660
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy (BNCT) using l-boronophenylalanine-fructose (l-BPA-F)
Study: 36269731
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of ketamine
Study: 36269797
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg/day orally; 14 days)
Study: 36269898
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion (target dose 0.75 × 10^6 CAR+ T cells/kg)
Study: 36269899
Drug: PET-adapted therapy
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-adapted therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim PET), followed by additional cycles based on PET results.
Study: 36269899
Drug: PET-adapted therapy
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-adapted therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim PET), followed by intensified treatment for PET2+ patients.
Study: 36270063
Drug: Low RNT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low RNT (L-RNT)
Study: 36270733
Drug: Durvalumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (750 mg every 2 weeks)
Study: 36270753
Drug: Danvatirsen monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danvatirsen monotherapy
Study: 36270753
Drug: Danvatirsen plus
Normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danvatirsen plus durvalumab combination therapy
Study: 36270753
Drug: Danvatirsen monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danvatirsen monotherapy and combination therapy
Study: 36270895
Drug: IGIV-C (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (2 g/kg loading dose over 2 days, maximum 80 g/d; maintenance doses of 1 g/kg every 3 weeks)
Study: 36271011
Drug: Weekly nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly nab-paclitaxel for three cycles
Study: 36271158
Drug: ZED8 (monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZED8 (monovalent antibody labeled with zirconium-89)
Study: 36272877
Drug: dTaP-IPV booster
Normalized name: DTaP-IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTaP-IPV booster vaccine
Study: 36272877
Drug: No pertussis-containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pertussis-containing vaccine
Study: 36272997
Drug: Hypothermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia treatment (HT) administered to 670 newborns (84.4%)
Study: 36273324
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (conventional-dose-rate photon radiotherapy at approximately 0.03 Gy/sec)
Study: 36273822
Drug: M3258, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3258, an orally bioavailable, potent, selective, reversible inhibitor of LMP7
Study: 36273986
Drug: MF59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted influenza A/H7N9 vaccine
Study: 36273986
Drug: Unadjuvanted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted influenza A/H7N9 vaccine
Study: 36274113
Drug: Stable compensated
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable compensated cirrhosis (CC) patients
Study: 36274263
Drug: Prophylactic donor
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic donor lymphocyte infusion (DLI) administered at 30 days after transplantation for HLA-matched related HSCT or at 45-60 days for haploidentical/unrelated HSCT.
Study: 36274263
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy (control group).
Study: 36274263
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy (including allo-HSCT and prophylactic DLI).
Study: 36274573
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or 12 months of treatment.
Study: 36275655
Drug: HIV Env
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV Env Mosaic immunogens combined with a liposomal toll-like receptor-4 adjuvant; monophosphoryl lipid A
Study: 36275715
Drug: Low-dose CD19-directed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy combined with Bruton's tyrosine kinase inhibitor and PD-1 antibody.
Study: 36275715
Drug: Low-dose CD19-directed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy.
Study: 36275912
Drug: BMS-986012 monotherapy
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986012 monotherapy
Study: 36276877
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in vaccine intent
Study: 36276877
Drug: Vaccine acceptability
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine acceptability related to mental health
Study: 36277662
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment group
Study: 36277757
Drug: Dual pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-dose rivaroxaban for 12 weeks.
Study: 36277757
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) monotherapy for a 4-weeks run-in period.
Study: 36278190
Drug: Meropenem therapy
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem therapy
Study: 36278416
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (SBP target 110-<130 mm Hg)
Study: 36278416
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (SBP target 130-<150 mm Hg)
Study: 36279023
Drug: PIK3CA mutations
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIK3CA mutations in SHR-positive HER2-negative breast cancer with aromatase inhibitors
Study: 36279162
Drug: General parenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: General parenting information (e.g., parental self-care, emotion regulation management)
Study: 36279618
Drug: Palbociclib (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (75, 100, and 125 mg PO daily on days 1 to 21 of a 28-day cycle) in combination with avelumab (10 mg/kg IV every 2 weeks) and cetuximab (400 mg/m)
Study: 36279618
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg) in combination with avelumab and cetuximab
Study: 36279618
Drug: Palbociclib, avelumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib, avelumab, and cetuximab combination
Study: 36279879
Drug: Hyper-CVAD chemotherapy
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyper-CVAD chemotherapy followed by blinatumomab consolidation (up to 28 μg/day for 28 days, given every 42 days)
Study: 36279879
Drug: Hyper-CVAD chemotherapy
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyper-CVAD chemotherapy followed by blinatumomab consolidation
Study: 36280578
Drug: Shockwave Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shockwave Therapy and Platelet-rich Plasma
Study: 36280861
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus evolocumab (dual therapy)
Study: 36280861
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus ezetimibe (triple therapy)
Study: 36280861
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 inhibitor therapy
Study: 36281165
Drug: End-tidal sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: End-tidal sevoflurane concentration for successful botulinum toxin injection
Study: 36281192
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of glycemia levels in patients with normal glycemia metabolism
Study: 36282533
Drug: Discussion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussion of HPV vaccine during PCP visit
Study: 36284220
Drug: pegcetacoplan (monthly)
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pegcetacoplan (monthly)
Study: 36284360
Drug: No Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Steroids (Control)
Study: 36285530
Drug: Conjugate vaccines,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccines, with some patients on preventive antibiotics (n = 6) and/or immunoglobulins replacement therapy (n = 10)
Study: 36285536
Drug: Lufotrelvir (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lufotrelvir (50, 150, 500, or 700 mg continuous 24-hour infusion)
Study: 36285536
Drug: Lufotrelvir (50-700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lufotrelvir (50-700 mg)
Study: 36285536
Drug: Lufotrelvir (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lufotrelvir (270 to 350 mg daily continuous infusion)
Study: 36286004
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride solution applied every 4 weeks
Study: 36286004
Drug: 5% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% potassium nitrate solution applied every 4 weeks
Study: 36286755
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg 24 hours before CT, 40 mg before CT, and 40 mg after CT (16 patients)
Study: 36286755
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg before CT and 40 mg after CT (33 patients)
Study: 36286755
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy (52 patients)
Study: 36286865
Drug: Specific drug
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific drug therapy